Clinical Otolaryngology · 1999 · 31 citations · 18 references
MedicineEndocrinologyPharmacologyBone MetabolismNeuroendocrinologySteroid BiochemistryAdrenal Axis RegulationBone EndocrinologyBone Metabolism DisordersCorticosteroid TherapyNasal PolyposisSteroid PharmacologyHpa Axis ActivityHpa Axis SuppressionHypothalamic-pituitary-adrenal Axis RegulationHypothalamic-pituitary-adrenal Axis SuppressionNasal DropsTopical Corticosteroid PreparationsTopical Nasal TherapyTreatment With Topical Corticosteroids
Betamethasone topical nasal drops may have systemic corticosteroid activity and cause suppression of the hypothalamo-pituitary-adrenal (HPA) axis and impairment of bone turnover. The aim of this study was to assess the effect of a standard 6-week regime of betamethasone topical nasal drops on the HPA axis (using a physiological dose (1 microg) ACTH test) and on bone turnover (using markers of bone turnover, urinary deoxypyridinoline and serum bone specific alkaline phosphatase). Eleven patients with nasal polyposis were included in a prospective cohort study. Plasma cortisol was lower after betamethasone treatment at all time intervals (P < 0. 0001). There was no change in urinary deoxypyridinoline corrected for creatinine or bone specific alkaline phosphatase. Six weeks' treatment with recommended doses of betamethasone suppresses the HPA axis, but has no significant effect upon markers of bone turnover. Topical betamethasone in subjects with nasal polyps should be viewed as systemic corticosteroid administration and the long and short-term sequelae should be borne in mind.
18
W. G. Scott-Brown, Alan Kerr · Medical Entomology and Zoology · 1997 · 558 citations
Medicine, Audiology, Otolaryngology +10
Gabriel Dickstein, Carmela Shechner, Wendell E. Nicholson et al. · The Journal of Clinical Endocrinology & Metabolism · 1991 · 462 citations
Intranasal drug delivery by spray and drops
J G Hardy, S W Lee, Clive Wilson · Journal of Pharmacy and Pharmacology · 1985 · 250 citations